Sprinklr Cuts 4% Of Workforce: Report

Customer experience firm Sprinklr, Inc (NYSE: CXM) reportedly laid off roughly 4% of its global workforce or more than 100 employees.
  • Customer experience firm Sprinklr, Inc (NYSE:CXM) reportedly laid off roughly 4% of its global workforce or more than 100 employees.
  • Sprinklr started the layoff drive last week and is cutting its workforce in India, the U.S., and other regions, TechCrunch reports.
  • The report cited a Sprinklr spokesperson who said the “strategic business decision” affected employees across certain targeted regions, segments, and support functions.
  • “While these decisions are extremely hard to make, it is the right decision for our long-term success as we shift from a capacity-driven to productivity-driven business model,” the spokesperson stated.
  • On February 7, Sprinklr notified the initial batch of its affected employees. It confirmed to TechCrunch that the decision did not impact any C-level executives.
  • The company had 3,245 employees as of Jan. 31, 2022. Of those, 933 were based in the U.S., and 2,312 were based internationally, including 1,580 in India.
  • Sprinklt cut at least 50 roles in its global marketing department in July, the report adds.
  • Sprinklr reported third-quarter revenue growth of 24% year-on-year to $157.3 million, marginally beating the consensus of $156.1 million.
  • Non-GAAP EPS of $0.02 beat the consensus loss of $(0.01).
  • Price Action: CXM shares traded lower by 0.09% at $11.01 on the last check Wednesday.
Total
0
Shares
Related Posts
Read More

Cannabis Stocks And ETFs Trading Higher As Government Recommendations Ignite Hope For Industry

Cannabis stocks and ETFs opened higher on Tuesday following the release of documents related to the Department of Health and Human Service's (HHS) review of cannabis. Investors are optimistic about potential regulatory changes that could benefit the cannabis industry after the US government released 252 pages of documents confirming the HHS's recommendation that the DEA reschedule cannabis as Schedule III under the Controlled Substances Act. The documents state that cannabis has a currently accepted medical use in treatment and potential for abuse less than drugs in Schedules I and II. In August, the Assistant Secretary for Health wrote a letter to the DEA calling for marijuana to be reclassified. The Secretary of HHS has confirmed that his department shared a comprehensive scientific review with the DEA in response to President Joe Biden's scheduling directive.

ACB